Update on Calcitonin Gene-Related Peptide Antagonism in the Treatment of Migraine.

The discovery of calcitonin gene-related peptide (CGRP) and its role in migraine has promoted a new era in migraine treatment: CGRP antagonism. Two classes of medications are currently available: small molecules targeting the CGRP receptor and monoclonal antibodies targeting the CGRP receptor or CGRP ligand. The revolution of these medications is represented by blurring the borders between acute and preventive treatments, episodic and chronic migraine, naïve and refractory patients and even between migraine and other headache disorders.

• Publication year

  2021

• Venue

  Neurologic clinics

• Publication date

  2021-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ncl.2020.09.001PMID 33223077
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Characterisation of the calcitonin gene-related peptide receptor antagonists ubrogepant and atogepant in human isolated coronary, cerebral and middle meningeal arteries

  2020cited by this paper
• Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study

  2020cited by this paper
• Efficacy and safety of eptinezumab in patients with chronic migraine

  2020cited by this paper
• Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial

  2020cited by this paper
• Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

  2020cited by this paper
• Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial.

  2019cited by this paper
• Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions

  2019cited by this paper
• Distribution of CGRP and CGRP receptor components in the rat brain

  2019cited by this paper
• Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.

  2019cited by this paper
• Orally Administered Atogepant Was Efficacious, Safe, and Tolerable for the Prevention of Migraine: Results From a Phase 2b/3 Study (S17.001)

  2019cited by this paper
• Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.

  2019cited by this paper
• Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.

  2019cited by this paper
• Two randomized migraine studies of galcanezumab

  2019cited by this paper
• Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial

  2019cited by this paper
• Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination

  2019cited by this paper
• Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine

  2019cited by this paper
• Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis

  2019cited by this paper
• Erenumab in chronic migraine with medication overuse

  2019cited by this paper
• European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

  2019cited by this paper
• Ubrogepant for the Treatment of Migraine.

  2019cited by this paper
• Migraine-related disability, impact, and health-related quality of life among patients with episodic migraine receiving preventive treatment with erenumab

  2018cited by this paper
• ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

  2018cited by this paper
• The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies

  2018cited by this paper
• Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post‐Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial

  2018cited by this paper
• Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers

  2018cited by this paper
• Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial

  2018cited by this paper
• Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial

  2018cited by this paper
• Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial

  2018cited by this paper
• Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

  2018cited by this paper
• A Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina

  2018cited by this paper
• Fremanezumab for preventive treatment of migraine

  2018cited by this paper
• Early onset of efficacy with erenumab in patients with episodic and chronic migraine

  2018cited by this paper
• 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double‐Blind, Placebo‐Controlled EVOLVE‐1 and EVOLVE‐2 Studies

  2018cited by this paper
• Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.

  2018cited by this paper
• A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

  2018cited by this paper
• Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE‐1, EVOLVE‐2, and REGAIN Randomized, Double‐Blind, Placebo‐Controlled Studies

  2018cited by this paper
• The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice

  2018cited by this paper
• Galcanezumab in chronic migraine

  2018cited by this paper
• Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017

  2018cited by this paper
• Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: A meta analysis.

  2017cited by this paper
• 75% responder rates provide improvement in HIT-6 scores from week 4 through 12 following a single infusion of ALD403, or placebo. (P2.165)

  2017cited by this paper
• Fremanezumab as Add‐On Treatment for Patients Treated With Other Migraine Preventive Medicines

  2017cited by this paper
• Erenumab (AMG 334) in episodic migraine

  2017cited by this paper
• Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial

  2017cited by this paper
• Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial.

  2017cited by this paper
• A Controlled Trial of Erenumab for Episodic Migraine

  2017cited by this paper
• Fremanezumab for the Preventive Treatment of Chronic Migraine

  2017cited by this paper
• Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial.

  2016cited by this paper
• A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine

  2016cited by this paper
• Localization of CGRP receptor components and receptor binding sites in rhesus monkey brainstem: A detailed study using in situ hybridization, immunofluorescence, and autoradiography

  2016cited by this paper
• Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

  2015cited by this paper
• Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study.

  2015cited by this paper
• BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial

  2014cited by this paper
• Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial.

  2014cited by this paper
• Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study.

  2014cited by this paper
• Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention

  2014cited by this paper
• Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine

  2013cited by this paper
• A Randomized, Placebo‐Controlled Study of the Effects of Telcagepant on Exercise Time in Patients With Stable Angina

  2012cited by this paper
• Randomized, Controlled Study of Telcagepant in Patients With Migraine and Coronary Artery Disease

  2012cited by this paper
• Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine

  2011cited by this paper
• Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion.

  2010cited by this paper
• Randomized, controlled trial of telcagepant for the acute treatment of migraine

  2009cited by this paper
• Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial.

  2008cited by this paper
• Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine.

  2004cited by this paper
• Involvement of calcitonin gene-related peptide in control of human fetoplacental vascular tone.

  2004cited by this paper
• Infusion of Pregnant Rats with Calcitonin Gene-Related Peptide (CGRP)8-37, a CGRP Receptor Antagonist, Increases Blood Pressure and Fetal Mortality and Decreases Fetal Growth1

  2002cited by this paper
• Vasoactive peptide release in the extracerebral circulation of humans during migraine headache

  1990cited by this paper

• Higher socioeconomic status is associated with dispensation of monoclonal antibodies against calcitonin gene-related peptide in migraine: A nested case-control study

  2025cites this paper
• Understanding the efficacy and tolerability of migraine treatment: a deep dive into CGRP antagonists

  2024cites this paper
• Efficacy and safety of galcanezumab for cluster headache preventive treatment: a systematic review and meta-analysis

  2024cites this paper
• Mode and site of action of therapies targeting CGRP signaling

  2023cites this paper
• Monoclonal antibodies to calcitonin gene-related peptide receptor for episodic migraine on the example of erenumab

  2023cites this paper
• The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression

  2023cites this paper
• Real-World Effectiveness of Calcitonin Gene-Related Peptide-Binding Monoclonal Antibodies for Migraine Prevention: A Systematic Review.

  2023cites this paper
• Calcitonin: current concepts and differential diagnosis

  2022cites this paper
• Peptide ligand interaction with maltose-binding protein tagged to the calcitonin gene-related peptide receptor: the inhibitory role of receptor N-glycosylation.

  2022cites this paper
• Systemic calcitonin gene-related peptide receptor antagonism decreases survival in a large animal model of polymicrobial sepsis: blinded randomised controlled laboratory trial.

  2022cites this paper
• Management of chronic migraine

  2022cites this paper
• Dietary omega 3 fatty acids for migraine

  2021cites this paper
• Effect of Collaborative Care for Persistent Postconcussive Symptoms on Academic Function: A Randomized Clinical Trial.

  2021cites this paper
• Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms

  2021cites this paper
• CGRP Inhibitors and Oxidative Stress Biomarkers in Resistant Migraine: A Real-Life Study with Erenumab, Fremanezumab, and Galcanezumab

  2021cites this paper
• Investigating Migraine-Like Behavior using Light Aversion in Mice.

  2021cites this paper
• Could erectile dysfunction be a side effect of CGRP inhibition? A case report

  2021cites this paper